WASHINGTON, June 3, 2026 /PRNewswire/ -- Digital University (DU) is advancing its mission as the Department of War's (DoW) enterprise training and readiness platform by...
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
ISS National Lab highlights space R&D and growing low Earth orbit economy at ASCEND 2026KENNEDY SPACE CENTER, Fla., June 2, 2026 /PRNewswire/ -- The International...
Lantra warns that a severe UK land-based skills shortage threatens the £41bn sector and food security, urging immediate Government action to close the gap.